These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37890357)

  • 1. Exploring the norepinephrine to angiotensin II conversion ratio in patients with vasodilatory hypotension: A post-hoc analysis of the ARAMIS trial.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    J Crit Care; 2024 Feb; 79():154453. PubMed ID: 37890357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
    Leisman DE; Handisides DR; Busse LW; Chappell MC; Chawla LS; Filbin MR; Goldberg MB; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Adams CD; Hodges TN; Bellomo R;
    Crit Care; 2024 Apr; 28(1):130. PubMed ID: 38637829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
    Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
    Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics.
    Morelli A; Tritapepe L; Rocco M; Conti G; Orecchioni A; De Gaetano A; Picchini U; Pelaia P; Reale C; Pietropaoli P
    Anesthesiology; 2005 Jan; 102(1):12-9. PubMed ID: 15618781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors.
    Boccara G; Ouattara A; Godet G; Dufresne E; Bertrand M; Riou B; Coriat P
    Anesthesiology; 2003 Jun; 98(6):1338-44. PubMed ID: 12766641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Burrell LM; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    Crit Care Med; 2024 Aug; 52(8):1218-1227. PubMed ID: 38511994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
    Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
    Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PILOT STUDY OF ANGIOTENSIN II AS PRIMARY VASOPRESSOR IN CRITICALLY ILL ADULTS WITH VASODILATORY HYPOTENSION: THE ARAMIS STUDY.
    See EJ; Clapham C; Liu J; Khasin M; Liskaser G; Chan JW; Serpa Neto A; Costa Pinto R; Bellomo R
    Shock; 2023 May; 59(5):691-696. PubMed ID: 36930693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
    Bellomo R; Forni LG; Busse LW; McCurdy MT; Ham KR; Boldt DW; Hästbacka J; Khanna AK; Albertson TE; Tumlin J; Storey K; Handisides D; Tidmarsh GF; Chawla LS; Ostermann M
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1253-1261. PubMed ID: 32609011
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin II for the Treatment of Vasodilatory Shock.
    Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
    N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.
    Bellomo R; Wunderink RG; Szerlip H; English SW; Busse LW; Deane AM; Khanna AK; McCurdy MT; Ostermann M; Young PJ; Handisides DR; Chawla LS; Tidmarsh GF; Albertson TE
    Crit Care; 2020 Feb; 24(1):43. PubMed ID: 32028998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial.
    Bokoch MP; Tran AT; Brinson EL; Marcus SG; Reddy M; Sun E; Roll GR; Pardo M; Fields S; Adelmann D; Kothari RP; Legrand M
    BMJ Open; 2023 Nov; 13(11):e078713. PubMed ID: 37984940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
    Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
    J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent.
    Argenziano M; Chen JM; Choudhri AF; Cullinane S; Garfein E; Weinberg AD; Smith CR; Rose EA; Landry DW; Oz MC
    J Thorac Cardiovasc Surg; 1998 Dec; 116(6):973-80. PubMed ID: 9832689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis.
    Corrêa TD; Jeger V; Pereira AJ; Takala J; Djafarzadeh S; Jakob SM
    Crit Care Med; 2014 Aug; 42(8):e550-9. PubMed ID: 24797374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support.
    Wieruszewski PM; Seelhammer TG; Barreto EF; Busse LW; Chow JH; Davison DL; Gaglani B; Khanna AK; Ten Lohuis CC; Mara KC; Wittwer ED
    J Intensive Care Med; 2023 May; 38(5):464-471. PubMed ID: 36524274
    [No Abstract]   [Full Text] [Related]  

  • 17. [Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II].
    Desachy A; Normand S; François B; Cassat C; Gastinne H; Vignon P
    Presse Med; 2000 Apr; 29(13):696-8. PubMed ID: 10797820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Agents for the Treatment of Vasodilatory Shock.
    Knotzer H; Poidinger B; Kleinsasser A
    Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial.
    Coulson TG; Miles LF; Zarbock A; Burrell LM; Patel SK; von Groote T; Pilcher D; Weinberg L; Landoni G; Bellomo R
    Br J Anaesth; 2023 Oct; 131(4):664-672. PubMed ID: 37481435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catecholamine-Sparing Effect of Angiotensin II in an Anephric Patient With Mixed Shock After Cardiac Revascularization Surgery: A Case Report.
    Cutler NS; Khanna AK
    A A Pract; 2020 Jul; 14(9):e01266. PubMed ID: 32909718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.